Agonist high- and low-affinity states of dopamine D2 receptors: Methods of detection and clinical implications

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 2, 2013, Pages 135-154

  Van Wieringen, Jan Peter ^a   Booij, Jan ^a   Shalgunov, Vladimir ^b   Elsinga, Philip ^b   Michel, Martin C ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

3H spiperone; Agonist high affinity state; Dopamine receptor; Psychosis

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE; RADIOLIGAND; RHODOPSIN; VESICULAR MONOAMINE TRANSPORTER;

ADENOHYPOPHYSIS; CALF (BOVINE); CANINE ADENOVIRUS; CELL MEMBRANE; CONCENTRATION (PARAMETERS); CORPUS STRIATUM; COW; CRYSTAL STRUCTURE; DRUG STRUCTURE; HUMAN; HYPOPHYSIS; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTOR AFFINITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SWINE; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; HUMANS; LIGANDS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2;

EID: 84873718668     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0817-0     Document Type: Review

References (154)

1. Abolfathi Z, Di Paolo T (1991) Modulation of dopamine receptor agonist binding sites by cations and estradiol in intact pituitary and 7315a tumors. Biochem Pharmacol 42:2163-2169
2. 3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci 57:1401-1410
3. Alttoa A, Seeman P, Koiv K, Eller M, Harro J (2009) Rats with persistently high exploratory activity have both higher extracellular dopamine levels and higher proportion of D(2) (High) receptors in the striatum. Synapse 63:443-446
4. Anzalone A, Lizardi-Ortiz JE, Ramos M, De Mei C, Hopf FW, Iaccarino C, Halbout B, Jacobsen J, Kinoshita C, Welter M, Caron MG, Bonci A, Sulzer D, Borrelli E (2012) Dual control of dopamine synthesis and release by presynaptic and postsynatpic D2 receptors. J Neurosci 32:9023-9034
5. Armstrong D, Strange PG (2001) Dopamine D2 receptor dimer formation - evidence from ligand binding. J Biol Chem 276:22621-22629
6. Auning E, Rongve A, Fladby T, Booij J, Hortobagyi T, Siepel FJ, Ballard C, Aarsland D (2011) Early and presenting symptoms of dementia with lewy bodies. Dement Geriatr Cogn 32:202-208
7. 3H]domperidone: a selective ligand for dopamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 308:231-237
8. 11C]-(+)-PHNO in drug-naïve Parkinson's disease. Brain 132:1366-1375
9. 11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 32:1353-1359
10. Booij J, Van Amelsvoort TA (2012) Imaging as tool to investigate psychoses and antipsychotics. Handb Exp Pharmacol 212:299-377
11. Booij J, Tissingh G, Winogrodzka A, Van Royen EA (1999) Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26:171-182
12. 123i]IBZM SPECT procedures. Eur J Nucl Med Mol Imag 35:1350-1356
13. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, De Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574
14. Briand LA, Flagel SB, Seeman P, Robinson TE (2008) Cocaine self-administration produces a persistent increase in dopamine D2 High receptors. Eur Neuropsychopharmacol 18:551-556
15. Burt DR, Creese I, Snyder SH (1977) Anti-schizophrenic drugs - chronic treatment elevates dopamine receptor-binding in brain. Science 196:327-328
16. Cannon M, Jones PB, Murray RM (2002) Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 159:1080-1092
17. Creese I, Burt DR, Snyder SH (1977) Dopamine receptor-binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197:596-598
18. Creese I, Padgett L, Fazzini E, Lopez F (1979) 3H-N-n- propylnorapomorphine: a novel agonist ligand for central dopamine receptors. Eur J Pharmacol 56:411-412
19. Cumming P (2011) Absolute abundances and affinity states of dopamine receptors in mammalian brain: a review. Synapse 65:892-909
20. Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U, Gjedde A (2002a) The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann Ny Acad Sci 965:440-450
21. 3H]propyl- norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J Cerebr Blood Flow Metabol 22:596-604
22. Curran C, Byrappa N, Mcbride A (2004) Stimulant psychosis: systematic review. Br J Psychiatry 185:196-204
23. De Lean A, Bf K, Mg C (1982) Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. Mol Phamacol 22:290-297
24. Di Paolo T, Levesque D (1988) Sodium and guanine nucleotide regulation of dopamine receptor agonist and antagonist binding sites in MtTW15 pituitary tumors. Can J Physiol Pharmacol 66:246-249
25. Dumbrille-Ross A, Seeman P (1987) Dopamine agonist high-affinity state in solubilized D2 receptors in striatum, but not in anterior pituitary. Biochem Pharmacol 36:2095-2099
26. 1 receptor. Brain Res 892:86-93
27. Elsinga PH, Hatano K, Ishiwata K (2006) Pet tracers for imaging of the dopaminergic system. Curr Med Chem 13:2139-2153
28. 3H]rauwolscine - a comparison of nine tissues and cell-lines. J Pharmacol Exp Ther 273:1287-1294
29. 3H]spiroperidol. Brain Res 136:578-584
30. Findell PR, Torkelson SM, Craig JC, Weiner RI (1988) Correlation of alpha- and beta-rotameric forms of 2-substituted octahydrobenzo[f]quinoline dopamine congeners with high and low affinity states of the anterior pituitary dopamine receptor and prolactin inhibition. Mol Phamacol 33:78-83
31. 11C]MNPA. Synapse 63:378-389
32. 11C]MNPA. Synapse 63:378-389
33. Finnema SJ, Bang-Andersen B, Wikstrom HV, Halldin C (2010) Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography. Curr Top Med Chem 10:1477-1498
34. Flagel SB, Robinson TE, Clark JJ, Clinton SM, Watson SJ, Seeman P, Phillips PEM, Akil H (2010) An animal model of genetic vulnerability to behavioral disinhibition and responsiveness to reward-related cues: implications for addiction. Neuropsychopharmacology 35:388-400
35. 3 dopamine receptor. J Pharmacol Exp Ther 268:417-426
36. Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, Torres GE, Kim KM, Lefkowitz RJ, Caron MG, Premont RT (2003) Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron 38:291-303
37. George S, Watanabe M, Paolo T, Falardeau P, Labrie F, Seeman P (1985) The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117:690-697
38. 2 receptors in vivo using positron emission tomography. J Neurochem 97:1089-1103
39. 11C]-raclopride pet study in cats. Neuropsychopharmacology 34:662-671
40. 11C]-(+)-PHNO pet study. Neuropsychopharmacology 34:1078-1086
41. 11]C-(+)-PHNO. Arch Gen Psychiatry 66:606-615
42. 3H]-domperidone labels only a single population of receptors which convert from high to low affinity for dopamine in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 332:21-25
43. 3H]PD 128907. Psychopharmacology 128:240-247
44. 3H-dopamine binding to rat striatal D-2 and D-3 sites: enhancement by magnesium and inhibition by guanine-nucleotides and sodium. Life Sci 30:1587-1595
45. 2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochem Pharmacol 33:877-887
46. Hein P, Bunemann M (2009) Coupling mode of receptors and G proteins. Naunyn-Schmiedeberg's Arch Pharmacol 379:435-443
47. Hein P, Michel MC (2005) Radioligand binding studies in cardiovascular research (saturation and competition binding studies). In: Dhein S, Mohr FW, Delmar M (eds) Practical methods in cardiovascular research. Springer, Heidelberg, pp 703-727
48. Hendriks-Balk MC, Peters SLM, Michel MC, Alewijnse AE (2008) Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. Eur J Pharmacol 585:278-291
49. Hirvonen J, Hietala J (2011) Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems. CNS Neurosci Ther 17:89-96
50. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776-786
51. 3H]-spiperone binding sites in various areas of the rat limbic system. Mol Phamacol 15:506-514
52. Huff RM, Molinoff PB (1982) Quantitative determination of dopamine receptor subtypes not linked to activation of adenylate cyclase in rat striatum. Proc Natl Acad Sci USA 79:7561-7565
53. 3H]sulpiride binding sites in rat striatal membranes. Brain Res 402:331-338
54. Insel PA, Stoolman LM (1978) Radioligand binding to beta adrenergic receptors of intact cultured S49 cells. Mol Phamacol 14:549-561
55. Jackson DM, Westlinddanielsson A (1994) Dopamine receptors: molecular-biology, biochemistry and behavioral-aspects. Pharmacol Ther 64:291-370
56. Juckel G, Friedel E, Koslowski M, Witthaus H, Ozgürdal S, Gudlowski Y, Knutson B, Wrase J, Brüne M, Heinz A, Schlagenhauf F (2012) Ventral striatal activation during reward processing in subjects with ultra-high risk for schizophrenia. Neuropsychobiology 66:50-56
57. 2 receptors. Progr Neuropsychopharmacol Biol Psychiatry 27:1081-1090
58. Kenakin T (1997) Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464
59. Kestler LP, Walker E, Vega EM (2001) Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 12:355-371
60. Kim DS, Szczypka MS, Palmiter RD (2000) Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci 20:4405-4413
61. high receptors in rats reared in social isolation. Synapse 63:476-483
62. 3H-raclopride - a potent substituted benzamide drug with high-affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259
63. Laruelle M (1998) Imaging dopamine transmission in schizophrenia. Q J Nucl Med 42:211-221
64. Laruelle M, Abidargham A, Vandyck CH, Rosenblatt W, Zeaponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB (1995) Spect imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190
65. 11C-NPA) determined from PET. J Nucl Med 50:814-817
66. 3H]spiperone. Eur J Pharmacol 81:273-285
67. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic super-sensitivity in Parkinson's disease. Nature 273:59-61
68. Levant B (2007) Characterization of dopamine receptors. In: Current protocols in pharmacology. 1.6.1-1.6.15. doi: 10.1002/0471141755.ph0106s36
69. 2-like dopamine receptors in rat brain. J Pharmacol Exp Ther 262:929-935
70. Levesque D, Diaz J, Pilon C, Martres M-P, Giros B, Souil E, Schott D, Morgat J-L, Schwartz J-C, Sokoloff P (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydrox-N, N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155-8159
71. Lipina TV, Niwa M, Jaaro-Peled H, Fletcher PJ, Seeman P, Sawa A, Roder JC (2010) Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav 9:777-789
72. longer receptor has a high-affinity state and inhibits adenylyl cyclase. Mol Brain Res 77:281-284
73. Mackay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH (1982) Increased brain dopamine and dopamine-receptors in schizophrenia. Arch Gen Psychiatry 39:991-997
74. 3 receptors: effects of ions and guanine nucleotides. J Pharmacol Exp Ther 274:790-797
75. 1-like receptors. Relevance for volume transmission in interpreting PET findings. Synapse 66:196-203
76. Martin GE, Williams M, Pettibone DJ, Zrada MM, Lotti VJ, Taylor DA, Jones JH (1985) Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo. J Pharmacol Exp Ther 233:395-401
77. 3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol 35:11-17
78. 2 receptor in vitro. Synapse 63:998-1009
79. Mccormick PN, Ginovart N, Wilson AA (2011) Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomograph radiotracers: implications for in vivo imaging of dopamine release. Mol Imag Biol 13:737-746
80. Metwally KA, Dukat M, Egan CT, Smith C, Dupre A, Gauthier CB, Herrick-Davis K, Teitler M, Glennon RA (1998) Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding. J Med Chem 41:5084-5093
81. 3H]tamsulosin. Eur J Pharmacol 342:85-92
82. + and guanine nucleotides. Nature 288:709-711
83. 3H] idazoxan and some other alpha 2-adrenergic drugs also bind with high-affinity to a nonadrenergic site. Mol Phamacol 35:324-330
84. 11C]-(+)-PHNO. Schizophr Res 131:63-68
85. Moncrieff J (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114:3-13
86. Morgante L, Colosimo C, Antonini A, Marconi R, Meco G, Pederzoli M, Pontieri FE, Cicarelli G, Abbruzzese G, Zappulla S, Ramat S, Manfredi M, Bottacchi E, Abrignani M, Berardelli A, Cozzolino A, Paradiso C, De Gaspari D, Morgante F, Barone P (2012) Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosur PS 83:76-82
87. 11C]raclopride in baboons. J Pharmacol Exp Ther 315:80-90
88. 3 receptor preferring agonist in vivo. Synapse 60:485-495
89. 11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 333:533-539
90. 11C]NPA positron emission tomography study. Synapse 65:1344-1349
91. Neumeyer JL, Gao YG, Kula NS, Baldessarini RJ (1990) Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist. J Med Chem 33:3122-3124
92. 3H]-YM-09151-2. Naunyn-Schmiedeberg's Arch Pharmacol 329:333-343
93. Novak G, Seeman P (2010) Hyperactive mice show elevated D2(High) receptors, a model for schizophrenia: Calcium/calmodulin-dependent kinase II alpha knockouts. Synapse 64:794-800
94. Novak G, Seeman P, Foll BL (2010) Exposure to nicotine produces an increase in dopamine D2(High) receptors: a possible mechanism for dopamine hypersensitivity. Int J Neurosci 120:691-697
95. 2 receptors and response to methamphetamine challenge in monkey brain. Synapse 63:534-537
96. 3O-N-n- propylnorapomorphine in the human brain. J Nucl Med 50:703-710
97. 3H]-raclopride. Synapse 64:624-633
98. Perreault ML, Seeman P, Szechtman H (2007) Kappa-opioid receptor stimulation quickens pathogenesis of compulsive checking in the quinpirole sensitization model of obsessive-compulsive disorder (OCD). Behav Neurosci 121:976-991
99. Perreault ML, Hasbi A, Alijaniaram M, Fan T, Varghese G, Fletcher PJ, Seeman P, O'dowd BF, George SR (2010) The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem 285:36625-36634
100. Pittman RN, Molinoff PB (1980) Interactions of agonists and antagonists with beta-adrenergic receptors on intact L6 muscle cells. J Cyclic Nucleotide Res 6:421-435
101. 3H]NGD 94-1. J Pharmacol Exp Ther 282:1020-1027
102. Qin K, Dong CM, Wu GY, Lambert NA (2011) Inactive-state preassembly of G(q)-coupled receptors and G(q) heterotrimers. Nat Chem Biol 7:740-747
103. Richfield EK, Young AB, Penney JB (1986) Properties of D2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. Brain Res 383:121-128
104. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18:247-291
105. 3H-remoxipride to membranes of rat liver and brain. Pharmacol Toxicol 76:29-35
106. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007) Breakthrough'' dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986
107. 11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-399
108. Seeman P (2008) Dopamine D2(High) receptors on intact cells. Synapse 62:314-318
109. Seeman P (2009) Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals. Synapse 63:186-192
110. Seeman P (2011) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 17:118-132
111. Seeman P (2012) Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. Synapse 66:88-93
112. 3H]apomorphine and an antipsychotic drug. Proc Natl Acad Sci U S A 73:4354-4358
113. Seeman P, Watanabe M, Grigoriadis D, Tedesco JL, George SR, Svensson U, Nilsson JLG, Neumeyer JL (1985) Dopamine D2 receptor-binding sites for agonists - a tetrahedral model. Mol Phamacol 28:391-399
114. Seeman P, Guan HC, Civelli O, Vantol HHM, Sunahara RK, Niznik HB (1992) The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands: implications for human brain positron emission tomography. Eur J Pharmacol 227:139-146
115. 3H]spiperone in isotonic medium: implications for human positron emission tomography. Synapse 49:209-215
116. Seeman P, Weinshenker D, Quirion R, Srivastava IAK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O'dowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD, Tallerico T (2005) Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci USA 102:3513-3518
117. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, Mcknight GS, Roder JC (2006) Psychosis pathways converge via D2high dopamine receptors. Synapse 60:319-346
118. Seeman P, Hall FS, Uhl G (2007a) Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61:573-576
119. 3H](+)PHNO. Synapse 61:263-267
120. Seeman P, Battaglia G, Corti C, Corsi M, Brun V (2009) Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse 63:247-251
121. 11C]raclopride. Synapse 59:260-269
122. 11C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cerebr Blood Flow Metabol 32:127-136
123. Shuto T, Seeman P, Kuroiwa M, Nishi A (2008) Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized rats. Eur J Neursoci 27:2551-2557
124. Sibley DR, Creese I (1983) Regulation of ligand-binding to pituitary D-2 dopaminergic receptors. Effects of divalent cations and functional group modification. J Biol Chem 258:4957-4965
125. Sibley DR, De Lean A, Creese I (1982) Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem 257:6351-6361
126. Sibley DR, Mahan LC, Creese I (1983) Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state Mol Phamacol 23:295-302
127. Simola N, Morelli M, Seeman P (2008) Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects. Synapse 62:394-397
128. Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR (2009) Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 And D3 dopamine receptors. Synapse 63:462-475
129. Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR, Innis RB (2010a) D2 receptor internalization prolongs
130. Skinbjerg M, Seneca N, Liow JS, Hong JS, Weinshenker D, Pike VW, Halldin C, Sibley DR, Innis RB (2010b) Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding. Synapse 64:699-703
131. Skinbjerg M, Sibley DR, Javitch JA, Abi-Dargham A (2012) Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction? Biochem Pharmacol 83:193-198
132. 3H-domperidone binding sites differ in rat striatum and pituitary. Naunyn-Schmiedeberg's Arch Pharmacol 327:221-227
133. Strange PG (2008) Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol 153:1353-1363
134. Sumiyoshi T, Seeman P, Uehara T, Itoh H, Tsunoda M, Kurachi M (2005) Increased proportion of high-affinity dopamine D2 receptors in rats with excitotoxic damage of the entorhinal cortex, an animal model of schizophrenia. Mol Brain Res 140:116-119
135. 3H]spiperone. Mol Phamacol 63456-63462
136. Tassin JP, Torrens Y, Salomon L, Lanteri C, Seeman P (2007) Elevated dopamine D2High receptors in alpha-1b-adrenoceptor knockout supersensitive mice. Synapse 61:569-572
137. Teeter MM, Froimowitz M, Stec B, Durand CJ (1994) Homology modeling of the dopamine D2 receptor and its testing by docking of agonists and tricyclic antagonists. J Med Chem 37:2874-2888
138. Tian WN, Deth RC (1993) Precoupling of Gi/G(o)-linked receptors and its allosteric regulation by monovalent cations. Life Sci 52:1899-1907
139. 11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54:264-277
140. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, Lemeur M, Piazza PV, Borrelli E (2000) Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408:199-203
141. 3H]N-0437, to striatal membranes. Eur J Pharmacol 143:101-107
142. Van Vliet LA, Rodenhuis N, Dijkstra D, Wikstrom H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Sundell S, Lundmark M (2000) Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3, 4,4a,10b-tetrahydro-4-n-Propyl-2H,5H-[1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). J Med Chem 43:2871-2882
143. 123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imag 34:502-507
144. Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9:557-569
145. Watanabe M, George SR, Seeman P (1985) Dependence of dopamine receptor conversion from agonist high- to low-affinity state on temperature and sodium ions. Biochem Pharmacol 34:2459-2463
146. 11C]-(+)-PHNO. Biol Psychiatry 59:389-394
147. 11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 33:279-289
148. Williams DR, Lees AJ (2005) Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. The Lancet Neurology 4:605-610
149. Wilson J, Lin H, Fu DY, Javitch JA, Strange PG (2001) Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. J Neurochem 77:493-504
150. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP (2007) The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6:628-639
151. Wreggett KA, Seeman P (1984) Agonist high- and low-affinity states of the D2-dopamine receptor in calf brain. Partial conversion by guanine nucleotide Mol Phamacol 25:10-17
152. Yang M, Verfurth F, Buscher R, Michel MC (1997) Is alpha1D-adrenoceptor protein detectable in rat tissues? Naunyn-Schmiedeberg's Arch Pharmacol 355:438-446
153. Zakzanis KK, Hansen KT (1998) Dopamine D2 densities and the schizophrenic brain. Schizophr Res 32:201-206
154. Zawarynski P, Tallerico T, Seeman P, Lee SP, O'dowd BF, George SR (1998) Dopamine D2 receptor dimers in human and rat brain. Febs Lett 441:383-386